Elevate Uranium Ltd
Elevate Uranium Ltd (EL8.AX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Elevate Uranium Ltd (EL8.AX), featuring income statements, balance sheets, and cash flow data.
Elevate Uranium Ltd (EL8.AX) Income Statement & Financial Overview
View the income breakdown for Elevate Uranium Ltd EL8.AX across both annual and quarterly reports.
Metric | Q4 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Cost of Revenue | $62916.00 | $58759.00 | $0.00 | $47470.00 |
Gross Profit | -$62916.00 | -$58759.00 | $0.00 | -$47470.00 |
Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
SG&A Expenses | $5.90M | $2233.00 | $2233.00 | $3.43M |
Operating Expenses | $5.90M | $2294.00 | $2294.00 | $3.43M |
Total Costs & Expenses | $5.96M | $2294.00 | $2294.00 | $3.48M |
Interest Income | $314261.00 | $161986.00 | $79.00 | $169589.00 |
Interest Expense | $3673.00 | $4498.00 | $0.00 | $4478.00 |
Depreciation & Amortization | $62916.00 | $29.00 | $29.00 | $47470.00 |
EBITDA | -$6.26M | -$2233.00 | -$2233.00 | -$3.73M |
EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | -$5.96M | -$2263.00 | -$2263.00 | -$3.48M |
Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
Other Income/Expenses (Net) | -$359540.00 | $47851.00 | $48.00 | -$309222.00 |
Income Before Tax | -$6.32M | -$2215.00 | -$2215.00 | -$3.79M |
Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
Income Tax Expense | -$355867.00 | $1.00 | $0.00 | $0.00 |
Net Income | -$6.32M | -$2215.00 | -$2215.00 | -$3.79M |
Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
EPS | -$0.02 | -$0.008 | -$0.008 | -$0.01 |
Diluted EPS | -$0.02 | -$0.008 | -$0.008 | -$0.01 |
Weighted Avg Shares Outstanding | $308.45M | $280.36M | $280.36M | $275.57M |
Weighted Avg Shares Outstanding (Diluted) | $308.45M | $280.36M | $280.36M | $275.57M |
Over the past four quarters, Elevate Uranium Ltd demonstrated steady revenue growth, increasing from $0.00 in Q4 2023 to $0.00 in Q4 2024. Operating income reached -$5.96M in Q4 2024, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$6.26M, reflecting operational efficiency. Net income dropped to -$6.32M, with EPS at -$0.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan